Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07621068

Hyperbaric Oxygen Therapy for Chronic Fatigue Syndrome (CFS)

This study evaluates the effects of hyperbaric oxygen therapy (HBOT) in patients with mild to moderate CFS/ME. Participants will undergo 60 HBOT sessions over 3 months with a 3-month follow-up, including physical, cognitive, imaging, and laboratory assessments.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The Sagol Center for Hyperbaric Medicine and Research Shamir Medical Center (Assaf Harofeh)

Zrifin, 70300, Israel

About this study

Hyperbaric oxygen therapy (HBOT) for Chronic Fatigue Syndrome (CFS)/Myalgic Encephalomyelitis (ME) - The aim of the current study is to evaluate the effect of HBOT on patients suffering for mild to moderate CFS. Patients will undergo a series of 60 HBOT over a span of 3 months, with a 3 month follow-up period. Patient's evaluation point includes the following tests: physical performance, questionnaires, cognitive tests, brain MRI, EEG, blood tests & muscle biopsy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject willing and able to read, understand and sign an informed consent
  • Diagnosis of mild to moderate severity of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
  • Patients diagnosed with CFS for more than 1 years
  • Stable psychological and pharmacological treatment for more than three months prior to inclusion

Exclusion criteria

  • Inability to attend scheduled clinic visits and/or comply with the study protocol
  • Severe and very severe cases of ME/CFS
  • History or diagnosis of, brain tumors, brain surgery, epilepsy, neurodegenerative diseases
  • Active malignancy
  • Substance use at baseline, except for prescribed cannabis if vaporized or taken PO as tincture
  • Active smokers
  • Chronic heart failure with ejection fraction of 30 or less
  • Chest pathology incompatible with pressure changes (including active asthma or COPD)
  • Ear or Sinus pathology incompatible with pressure changes (above 3 otolaryngologist visits a year)
  • Pregnancy
  • An inability to perform an awake brain MRI
  • An inability to perform Neurotrax
  • Participation in another medical study
  • HBOT for any reason prior to study enrolment

Treatment and study plan

hyperbaric oxygen therapy

Device

60 consecutive sessions of breathing 100% oxygen by mask at 2 ATA for 90 minutes with 5-minute air breaks every 20 minutes, 5 sessions per week within a three months' period.

Sham treatment

Device

60 consecutive sessions of breathing 21% oxygen by mask at 1 ATA for 90 minutes with 5-minute air breaks every 20 minutes, 5 sessions per week within a three months' period.

Primary outcomes

  1. Cardiopulmonary exercise test (CPET)

    Time frame: Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session, End of study evaluation: at the end of 3 month follow-up period

    Physical performance evaluated by cardiopulmonary exercise test (CPET) on a bicycle or a treadmill. CPET will be used to determine the peak oxygen consumption (Peak VO2), first ventilatory threshold (VT1) and if possible, the second ventilatory threshold (VT2).

Secondary outcomes

  1. DePaul Post-Exertional Malaise Questionnaire (DPEMQ)

    Time frame: Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session, End of study evaluation: at the end of 3 month follow-up period

    A self-report instrument assessing the frequency and severity of post-exertional malaise symptoms in individuals with ME/CFS.

    Total scores typically range from the minimum value (no symptoms) to the maximum value (most severe and frequent symptoms), with higher scores indicating worse post-exertional malaise.

  2. Short Form-36 Health Survey (SF-36)

    Time frame: Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session, End of study evaluation: at the end of 3 month follow-up period

    A self-reported measure of health-related quality of life across eight domains. Each SF-36 scale is transformed to a 0 to 100 score, where 0 represents the worst health status and 100 represents the best health status.

    Higher scores indicate better health-related quality of life.

  3. Pittsburgh Sleep Quality Index (PSQI)

    Time frame: Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session, End of study evaluation: at the end of 3 month follow-up period

    a self-report questionnaire that assesses sleep quality and disturbances over the previous month.

    The measure consists of 19 individual items, creating 7 components that produce one global score.

    The score ranges from 0 to 21, with higher scores indicating poorer sleep quality.

  4. Brief Symptom Inventory-18 (BSI-18)

    Time frame: Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session, End of study evaluation: at the end of 3 month follow-up period

    The BSI-18 will be used to evaluate psychological distress. An 18 item self-report questionnaire which generates a global stress index (GSI), and three subscales: depression, anxiety, and somatization.

    Each item is rated on a 5-point scale, with distress ratings ranging from 0 (not at all) to 4 (extremely).

    Higher scores indicate greater psychological distress.

  5. Montreal Cognitive Assessment (MoCA)

    Time frame: Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session, End of study evaluation: at the end of 3 month follow-up period

    A brief cognitive screening tool with high sensitivity and specificity for detecting mild cognitive impairment (MCI).

    The MoCA total score ranges from 0 to 30, with higher scores indicating better cognitive performance.

    A score of 26 or above is considered normal and a score lower than 26 is the cutoff point for diagnosis of cognitive impairment.

  6. NeuroTrax

    Time frame: Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session, End of study evaluation: at the end of 3 month follow-up period

    NeuroTrax (NeuroTrax Corp., Houston, TX) is a computerized neurocognitive battery of tests used to assess brain wellness across multiple cognitive domains, including memory, executive function, visual spatial perception, verbal function, attention, information processing speed, and motor skills

  7. Brain MRI

    Time frame: Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session, End of study evaluation: at the end of 3 month follow-up period

    Images will be acquired on MAGNETOM Vida 3T Scanner, T1-weighted images will be used for gray matter and hippocampal volumetric measurement.

    Statistical parametric mapping software SPM12, will be used for brain segmentation.

    Voxel-based morphometry (VBM) procedure to calculate the whole-brain volumes.

  8. Brain EEG

    Time frame: Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session, End of study evaluation: at the end of 3 month follow-up period

    Resting-state and task-related brain EEG measures.

    EEG will be recorded using a high-density dry-electrode system (115 channels, EEG-Sense, Israel).

    Recordings will include eyes-open rest (3 minutes), eyes-closed rest (3 minutes), and 20 minutes of cognitive tasks (N-Back, Stroop, Flanker, and multiple-object tracking).

    EEG data will undergo standard preprocessing (filtering, line-noise and artifact removal, and down-sampling).

    Primary EEG outcomes will include spectral measures (peak frequency and relative power; alpha, beta, theta, and delta band power), power spectral distribution, and functional connectivity indices.

    Event-related potentials will be extracted for the cognitive tasks, including event-related synchronization and desynchronization (ERS/ERD), with averages computed across artifact-free trials.

  9. Sleep EEG

    Time frame: Baseline (3 consecutive nights within 2 weeks before treatment), post-treatment (3 consecutive nights within 21±7 days after last HBOT/Sham session), and at the end of the 3-month follow-up period (3 consecutive nights)

    Physiological sleep EEG signals will be collected using a home wearable EEG headband (Muse S) paired with a mobile application.

    Multi-channel EEG will be recorded from frontal and temporal locations, together with inertial sensors to capture movement and head position.

    Primary sleep EEG outcomes will include validated sleep-wake classification and sleep staging metrics (percent time in light, deep, and REM sleep), sleep timing (bedtime, sleep onset, awakenings, final wake time), and sleep continuity indices (wake after sleep onset and sleep efficiency).

    Secondary analyses will include signal-level EEG features such as spectral power in conventional frequency bands and spindle-like activity.

    Higher sleep efficiency and higher proportions of deep (slow-wave) sleep will be interpreted as better sleep quality.

  10. Orthostatic Intolerance - 10-min NASA Lean Test (NLT)

    Time frame: Baseline, monthly during treatment (3 months), at the post-treatment evaluation (within 21±7 days after last HBOT/Sham session), monthly during follow-up (3 months), at the end of the follow-up period (end of study evaluation).

    The 10-min NASA Lean Test (NLT) will be performed by asking the subject to lay supine for 10 min and then leaning against a wall for 10 min, while blood pressure and heart rate are measured

  11. Body Composition

    Time frame: Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session, End of study evaluation: at the end of 3 month follow-up period

    Body composition will be assessed using the seca mBCA Ultra, a clinically validated segmental multi-frequency bioelectrical impedance analysis (SMF-BIA) system.

    The device estimates fat mass, fat-free mass, skeletal muscle mass, and total body water based on multi-frequency impedance measurements across body segments.

    Outcomes will include absolute values (kg or liters) and relative values (percentage of body weight) for each compartment. Higher fat mass and body fat percentage indicate greater adiposity, whereas higher fat-free mass and skeletal muscle mass indicate greater lean tissue.

  12. Hand Grip test

    Time frame: Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session, End of study evaluation: at the end of 3 month follow-up period

    Quick, non invasive assessment of the maximal force generated when squeezing a hand dynamometer. Reflecting strength of the hand and forearm muscles and serving as a proxy for overall muscle weakness, fatigability, and disease severity

  13. Peripheral blood biomarkers

    Time frame: Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session, End of study evaluation: at the end of 3 month follow-up period

    Whole blood and plasma will be collected and stored for future biomarker analysis

  14. Muscle biopsy

    Time frame: Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session.

    A voluntary test. Participants will undergo a muscle biopsy using a 0.3mm Trucut needle in an aseptic technique. Muscle sample will be analysed using the Oxygraph (Oroboros Inc, Austria) for oxygen respiratory function, as well as staining for mitochondrial proteins and Mitochondrial DNA.

Study contacts

Contact information is provided by the study sponsor or research team.

Eli Kravchik, MD

CONTACT

[email protected]

089779241

Shai Efrati, Prof

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Assaf-Harofeh Medical Center

Other Gov

Registry information

Official study title

Hyperbaric Oxygen Therapy for Chronic Fatigue Syndrome (CFS) - A Prospective, Randomized, Double-Blind, Sham-Controlled Study

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jun 2, 2026
Registry last updated
Jun 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.